Recent innovations in cell culture media are set to make the development and manufacture of monoclonal antibodies (mAbs) more affordable. Historically, the use of animal-derived ingredients in cell culture media has driven up costs and limited research and development. However, new technology using recombinant albumin derived from baker’s yeast promises high quality and consistency, reducing costs and making life-saving treatments more accessible. This breakthrough has the potential to revolutionize the field of biological therapeutics. 💉🔬👩🔬
📢 Game-Changing Breakthrough Makes Monoclonal Antibodies Affordable
Introduction:
This article discusses the high cost of cell culture media and the limitations of existing ingredients in the production of monoclonal antibodies (mAbs). It introduces a new approach using Quantitative Trait Loci (QTL) technology to create affordable and high-quality recombinant albumin, transferrin, and growth factors for cell culture media production.
Main points:
- The high cost of cell culture media limits research experiments, raises the cost of batches for clinical testing, and drives up healthcare prices.
- Existing ingredients, such as animal-derived albumin, have limitations in quality and safety, and chemically defined media is expensive and has technical barriers.
- QTL technology enables the creation of high-quality recombinant albumin from Saccharomyces cerevisiae (baker’s yeast) that is suitable for inclusion in chemically defined media.
- Affordable high-quality recombinant albumin and other key cell culture media ingredients will lower the cost of research and development and make therapies more accessible.
- QTL technology offers potential benefits for the biological therapeutics market by reducing the financial burden on developers and lowering costs for existing monoclonal antibody therapies.
Conclusion:
The use of QTL technology to create affordable and high-quality recombinant albumin and other key cell culture media ingredients has the potential to revolutionize the production of monoclonal antibodies and other biological therapeutics. It will lower costs, increase accessibility, and drive innovation in the field of biopharmaceutical manufacturing.
